Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19 and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers.
Year founded2013
Served areaWorldwide
Headcount762
Headquarters6 Rue Alain Bombard, 44800 Saint-Herblain – France
107,781,582
IPOJune 28, 2007
Stock exchange(s)Euronext Paris